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Hypoxia in solid tumors: biological responses  
to hypoxia and implications on therapy and prognosis
Abstract
Tumor development, promotion and ability to spread depend greatly on 
tumor microenvironment. Rapid growth accompanied by inadequate angio-
genesis is the reason why most solid tumors contain hypoxic regions. Activation 
of hypoxia signaling pathways stimulates neoangiogenesis, alters tumor me-
tabolism, promotes a more aggressive tumor behavior and significantly affects 
its responsiveness to therapy. Growing amount of evidence suggest that hy-
poxia induces transcription of tumor promoting genes leading to increased 
tumor cell proliferation and metastatic potential. Improved understanding of 
molecular pathways will enable establishment of useful prognostic and predic-
tive factors, along with more effective treatment options.
INTRODUCTION
In addition to being an essential molecule for oxidative phosphoryla-tion in mitochondria, oxygen also functions as an important signaling 
molecule and regulates a wide range of biological processes, including 
erythropoiesis, angiogenesis, and cellular differentiation (1). Hypoxic 
regions are common characteristic of majority of solid neoplasms, result-
ing from discordance between high metabolic needs of rapid growing 
malignant tissues and oxygen supply through structurally and function-
ally impaired microvasculature. Recognition of tumor hypoxia and its 
clinical significance was hampered for a long time by a lack of standard-
ized methods for routine measurement of intra-tumor partial oxygen 
pressure (2, 3). In the past decade, considerable progress has been made 
in the field of tumor oxygenation and its impact on tumor promotion, 
and metastatic potential, therapeutic response and prognosis in patients 
with solid malignant neoplasms (4).
Research shows relative resistance of tumorous tissue against ionizing 
radiation, chemotherapy and other non-surgical treatment modalities 
(5). Hypoxia is believed to be a key microenvironment factor that in-
duces tumor metastasis. It amplifies adaptations that enable tumor cell 
survival (anaerobic shift, neovascularization, resistance to apoptosis) 
and, on the other hand stimulates tumor aggressiveness (gene instabil-
ity, invasion, metastasis, dedifferentiation) (6).
METABOLIC CHANGES OF TUMOR CELLS IN 
HYPOXIA
Tumor microenvironment is metabolically heterogeneous; cells close 
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on oxidative metabolism, whereby distant cells are poorly 
oxygenated and glycolysis-dependant. Adaptive changes 
in cell metabolism of tumor cells involve shift from oxida-
tive phosphorylation to glycolysis, increased glycogen 
synthesis; switch from glucose to glutamine as a major 
substrate for fatty acid synthesis (1).
Cellular response to hypoxia is modulated by a family 
of ubiquitous transcription factors known as hypoxia in-
ducible factors (HIF), comprising HIF-1a, HIF-2a and 
HIF-3a (Figure 1). Metabolic reprogramming is coordi-
nated on a transcription level of hypoxia inducible factor 
1 (HIF-1), considered to be a main regulator of oxygen 
supply and demand (7) (Figure 1).
In hypoxic cells HIF-1 increases expression of glucose 
transporters, glycolytic enzymes (e.g. LDH-A, MCT-4) 
that stimulate glucose uptake, conversion to lactate and 
lactate efflux from the cell. On the other hand, well oxy-
genated cells express MCT-1 and LDH-B, that mediate 
lactate transport intracellularly and its conversion into 
pyruvate needed for oxidative metabolism (8).
Role of hypoxia inducible factor (HIF-1)
HIF-1 is a heterodimer comprised of HIF-1a and HIF-
1b subunits. HIF-1a expression is regulated by oxygen and 
degrades swiftly in normoxic conditions. On the other 
hand, hypoxia stabilizes HIF-1a and results in its accumu-
lation. HIF-1b is constitutively expressed. However, in 
certain conditions of adequate oxygenation, HIF-1a expres-
sion can increase. HIF-1 in tumor cells can be activated by 
the loss of function of tumor suppressor genes (e.g. VHL) 
and/or oncogene gain of function with resulting increase 
in activity of e.g. PI3K/AKT/mTOR signal pathways (9).
Modes of HIF-1 protein level increase are diverse. For 
example, von Hippel-Lindau protein mutation stabilizes 
HIF-1a protein, while activation of PI3K/AKT/mTOR 
signal pathway stimulates HIF-1a mRNA translation. 
Reactive oxygen and nitrogen species inhibit HIF-1a pro-
teasome. Following stabilization of HIF-1a, heterodimer 
protein activates transcription of numerous genes in-
volved in angiogenesis, proliferation, glycolytic tumor 
metabolism and regulation of cellular pH (9).
HIF-1 is a mediator of metabolic alterations that gov-
ern tumor progression and resistance to treatment. In-
hibitors of HIF or metabolic enzymes can impair tumor 
cell flexibility and render them more susceptible to anti-
neoplastic regimens (10).
HIF family also contributes to transactivation of genes 
that encode micro RNA molecules (miRs). Micro RNAs 
Figure 1. Hypoxia upregulates various transcription factors. HIF (hypoxia-inducible factor) plays a key role inducing transcription of genes in-
volved in tumor progression, angiogenesis, erythropoiesis, metabolism, apoptosis and tissue remodelling.
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are small regulatory RNA molecules that bind specific 
messenger RNA (mRNA) sequences, and thereby inhib-
it translation or stimulate their degradation. Many cell 
types show increased miR-210 expression typical for a 
hypoxic response (11).
HYPOXIA AND CANCER METASTASIS
Majority of solid tumors have hypoxic areas. Measure-
ments of tissue oxygenation in breast cancer have shown 
correlation between large areas of hypoxic tissue and ex-
pression of hypoxic markers detected by immunolocaliza-
tion methods. Staining for CAIX and HIF-1a in breast 
cancer tissues shows high intensity surrounding necrotic 
areas. In pre-clinical models, efficient deletion of HIF-1a 
inhibits primary tumor growth, suppresses lung metasta-
sis and prolongs survival. Loss of HIF-1a inhibits expres-
sion of markers of basal breast cancer phenotype, as well 
as numerous genes involved in epithelial-mesenchymal 
transition (12).
Expression of numerous genes associated with breast 
cancer metastasis is increased in hypoxic conditions, 
correlating with worse outcome (13, 14). Better under-
standing of molecular pathways involving hypoxia-
stimulated breast cancer metastasis could result in po-
tentially beneficial, prognostic as well as therapeutic 
implications (15, 16).
THERAPEUTIC IMPLICATIONS OF 
TUMOR HYPOXIA
Effect of hypoxia to radiotherapy 
treatment
HIF-1 protein has an important role in tumor resis-
tance against radiotherapy treatment, either through post-
irradiation protection against neoangiogenesis or through 
amplified anti-oxidative capacity as a component of gly-
colytic tumor metabolism.
In preclinical trials, blockage of HIF-1a and tumor 
glucose metabolism affects tumor microenvironment, 
stimulates metabolic alterations and sensitizes various 
solid tumors to radiation. Future research should eluci-
date weather HIF-1 inhibitors and inhibitors of glucose 
metabolism could prove beneficial in clinical practice. 
Special attention should be focused on effects of HIF-1 
inhibition on tumor glycolytic and redox potential. Op-
timal timing for introduction of these inhibitors during 
the treatment course is yet to be established (17).
In order to optimize patients suitable for such treat-
ment, it is necessary to additionally validate imaging tech-
niques for determination of HIF-1 protein expression, 
changes in glucose metabolism and thereby response to 
radiotherapy treatment (18). PET imaging of hypoxia can 
be used to identify patients with hypoxic tumors who 
could benefit most from additional treatment, either by 
prescribing hypoxia-modifying drugs or by increasing the 
radiation dose to the tumor (19).
Hypoxia-mediated resistance to 
chemotherapy treatment
Hypoxia in solid tumors is associated with develop-
ment of chemo-resistance. Majority of research focuses on 
the impact of hypoxia on apoptotic effect of cytotoxic 
medications, while minority refers to non-apoptotic path-
ways of chemo-resistance in hypoxia (20). Multiple mech-
anisms of hypoxia-mediated chemo-resistance are shown 
in MDA-MB 231 breast cancer cell line. Hypoxic precon-
ditioning of these breast cancer cells results in resistance 
to multiple categories of chemotherapy medications: an-
thracyclines, etoposide, mitoxantrone. Acute exposure to 
these medications results in multiple nuclear and cyto-
plasmic changes (15).
Cells with higher expression of HIF-1a have better ef-
ficacy in double strand DNA repair, increased resistance 
to carboplatin, etoposide and ionizing radiation in com-
parison HIF-1a deficient cells. Hypoxia can stimulate 
chemo-resistance to doxorubicin in experimental models 
of MCF-7 and HCC1973 cell lines. Likewise, that same 
resistance of the aforementioned cell lines can be amelio-
rated through the addition of tanshinone IIA compound 
(Tan IIA). The assumed mechanism of Tan IIA effect is 
attributed to reduced expression of HIF-1a (12). In addi-
tion to doxorubicin resistance, hypoxia contributes to 
enhanced epithelial-mesenchymal transition through 
modulated expression of E-cadherin and vimentin protein 
levels. Hypoxia reduces E-cadherin expression and in-
creases vimentin expression. Tan IIA returns their expres-
sion to a control level (12). These effects need to be con-
firmed in additional in vivo research.
Biological therapy in hypoxic 
microenvironment
For long it was presumed that anti-angiogenic medica-
tions have an important role in cancer management. Re-
cent clinical studies question their effectiveness in breast 
cancer. Pre-clinical trials suggest that anti-angiogenic 
medications could even increase invasive and metastatic 
potential of breast cancer cells. Through stimulation of 
intra-tumor hypoxia in breast cancer xenografts, sunitinib 
and bevacizumab lead to proliferation of tumor stem cell 
population.
Pre-clinical trials indicate that inhibitors of dichloro-
acetate DCA and HIF inhibitors could enhance cur-
rently limited efficacy of anti-VEGF antibody bevaci-
zumab as angiogenesis inhibitor (21, 22).
Melanomas that have the V600E BRAF mutation ex-
hibit increased HIF-1a expression. Vemurafenib target-
ing mutated BRAF was approved for the treatment of 
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advanced melanomas. Resistance to vemurafenib is being 
increasingly recognized. Vemurafenib-resistant melano-
mas respond to treatment with an increase in HIF-1a 
levels, which thus serves as one of the mechanism of their 
resistance (23).
CONCLUSION
Hypoxic areas are present in many solid tumors due to 
inadequate blood supply and deranged vascular architec-
tonics. Tumor cells therefore adapt to hypoxic conditions 
in order to maintain their own balance of oxygen homeo-
stasis.
Cell adaptation to hypoxia involves well coordinated 
expression of various groups of genes, many of which are 
transcriptionally regulated by hypoxia-inducible factor 1 
(HIF-1). HIF-1 is a transcription factor made up of HIF-
1a and HIF-1b subunits. HIF-1b is constitutively ex-
pressed, and control of HIF-1 function is accomplished 
through oxygen-dependant degradation of the alpha sub-
unit. Active HIF-1 induces expression of many genes, 
some of which are relevant for tumor progression (24).
Prevailing evidence from experimental and clinical tri-
als indicate tight association of tumor cell adaptation to 
hypoxia with tumor progression as well as contribution 
to development of resistance to specific oncological treat-
ment modalities (ionizing radiation, cytotoxic medica-
tions, targeted biological therapy).
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